These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 19568884)

  • 21. Serum mesothelin for early detection of asbestos-induced cancer malignant mesothelioma.
    Creaney J; Olsen NJ; Brims F; Dick IM; Musk AW; de Klerk NH; Skates SJ; Robinson BW
    Cancer Epidemiol Biomarkers Prev; 2010 Sep; 19(9):2238-46. PubMed ID: 20651076
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Calretinin as a blood-based biomarker for mesothelioma.
    Johnen G; Gawrych K; Raiko I; Casjens S; Pesch B; Weber DG; Taeger D; Lehnert M; Kollmeier J; Bauer T; Musk AW; Robinson BWS; Brüning T; Creaney J
    BMC Cancer; 2017 May; 17(1):386. PubMed ID: 28558669
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Validity of mesothelin in occupational medicine practice.
    Smolková P; Nakládalová M; Zapletalová J; Jakubec P; Vildová H; Kolek V; Petřek M; Nakládal Z
    Int J Occup Med Environ Health; 2016; 29(3):395-404. PubMed ID: 26988879
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Midkine is a potential novel marker for malignant mesothelioma with different prognostic and diagnostic values from mesothelin.
    Ak G; Tada Y; Shimada H; Metintas S; Ito M; Hiroshima K; Tagawa M; Metintas M
    BMC Cancer; 2017 Mar; 17(1):212. PubMed ID: 28335760
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Possible reversibility between epithelioid and sarcomatoid types of mesothelioma is independent of ERC/mesothelin expression.
    Kojima M; Kajino K; Momose S; Wali N; Hlaing MT; Han B; Yue L; Abe M; Fujii T; Ikeda K; Hino O
    Respir Res; 2020 Jul; 21(1):187. PubMed ID: 32677949
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Megakaryocyte potentiating factor as a tumor marker of malignant pleural mesothelioma: evaluation in comparison with mesothelin.
    Iwahori K; Osaki T; Serada S; Fujimoto M; Suzuki H; Kishi Y; Yokoyama A; Hamada H; Fujii Y; Yamaguchi K; Hirashima T; Matsui K; Tachibana I; Nakamura Y; Kawase I; Naka T
    Lung Cancer; 2008 Oct; 62(1):45-54. PubMed ID: 18394747
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sensitivity of urinary mesothelin in patients with malignant mesothelioma.
    Creaney J; Musk AW; Robinson BW
    J Thorac Oncol; 2010 Sep; 5(9):1461-6. PubMed ID: 20815094
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Establishment of novel mAb to human ERC/mesothelin useful for study and diagnosis of ERC/mesothelin-expressing cancers.
    Ishikawa K; Segawa T; Hagiwara Y; Maeda M; Abe M; Hino O
    Pathol Int; 2009 Mar; 59(3):161-6. PubMed ID: 19261093
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combination of mesothelin and CEA significantly improves the differentiation between malignant pleural mesothelioma, benign asbestos disease, and lung cancer.
    Muley T; Dienemann H; Herth FJ; Thomas M; Meister M; Schneider J
    J Thorac Oncol; 2013 Jul; 8(7):947-51. PubMed ID: 23777840
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mesothelin-family proteins and diagnosis of mesothelioma.
    Robinson BW; Creaney J; Lake R; Nowak A; Musk AW; de Klerk N; Winzell P; Hellstrom KE; Hellstrom I
    Lancet; 2003 Nov; 362(9396):1612-6. PubMed ID: 14630441
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Environmental carcinogenesis - 100th anniversary of creating cancer.
    Imai M; Hino O
    Cancer Sci; 2015 Nov; 106(11):1483-5. PubMed ID: 26310516
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combined CA125 and mesothelin levels for the diagnosis of malignant mesothelioma.
    Creaney J; van Bruggen I; Hof M; Segal A; Musk AW; de Klerk N; Horick N; Skates SJ; Robinson BW
    Chest; 2007 Oct; 132(4):1239-46. PubMed ID: 17646232
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Deficiency of the Erc/mesothelin gene ameliorates renal carcinogenesis in Tsc2 knockout mice.
    Zhang D; Kobayashi T; Kojima T; Kanenishi K; Hagiwara Y; Abe M; Okura H; Hamano Y; Sun G; Maeda M; Jishage K; Noda T; Hino O
    Cancer Sci; 2011 Apr; 102(4):720-7. PubMed ID: 21205090
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma.
    Hollevoet K; Nackaerts K; Thimpont J; Germonpré P; Bosquée L; De Vuyst P; Legrand C; Kellen E; Kishi Y; Delanghe JR; van Meerbeeck JP
    Am J Respir Crit Care Med; 2010 Mar; 181(6):620-5. PubMed ID: 20075387
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prediagnostic detection of mesothelioma by circulating calretinin and mesothelin - a case-control comparison nested into a prospective cohort of asbestos-exposed workers.
    Johnen G; Burek K; Raiko I; Wichert K; Pesch B; Weber DG; Lehnert M; Casjens S; Hagemeyer O; Taeger D; Brüning T;
    Sci Rep; 2018 Sep; 8(1):14321. PubMed ID: 30254313
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serial measurements of mesothelioma serum biomarkers in asbestos-exposed individuals: a prospective longitudinal cohort study.
    Hollevoet K; Van Cleemput J; Thimpont J; De Vuyst P; Bosquée L; Nackaerts K; Germonpré P; Vansteelandt S; Kishi Y; Delanghe JR; van Meerbeeck JP
    J Thorac Oncol; 2011 May; 6(5):889-95. PubMed ID: 21358346
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development of positron emission tomography imaging by 64Cu-labeled Fab for detecting ERC/mesothelin in a mesothelioma mouse model.
    Yoshida C; Sogawa C; Tsuji AB; Sudo H; Sugyo A; Uehara T; Hino O; Yoshii Y; Fujibayashi Y; Fukumura T; Koizumi M; Arano Y; Saga T
    Nucl Med Commun; 2010 May; 31(5):380-8. PubMed ID: 20072072
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Megakaryocyte potentiation factor cleaved from mesothelin precursor is a useful tumor marker in the serum of patients with mesothelioma.
    Onda M; Nagata S; Ho M; Bera TK; Hassan R; Alexander RH; Pastan I
    Clin Cancer Res; 2006 Jul; 12(14 Pt 1):4225-31. PubMed ID: 16857795
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Inhibitory Effects of Anti-ERC/Mesothelin Antibody 22A31 on Colorectal Adenocarcinoma Cells, within a Mouse Xenograft Model.
    Taniguchi G; Kajino K; Momose S; Saeki H; Yue L; Ohtsuji N; Abe M; Shibuya T; Orimo A; Nagahara A; Watanabe S; Hino O
    Cancers (Basel); 2022 Apr; 14(9):. PubMed ID: 35565327
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of renal failure on the tumor markers of mesothelioma, N-ERC/mesothelin and osteopontin.
    Shiomi K; Shiomi S; Ishinaga Y; Sakuraba M; Hagiwara Y; Miyashita K; Maeda M; Suzuki K; Takahashi K; Hino O
    Anticancer Res; 2011 Apr; 31(4):1427-30. PubMed ID: 21508397
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.